Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.
2.

EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.

Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z.

Mod Pathol. 2010 May;23(5):644-53. doi: 10.1038/modpathol.2010.50. Epub 2010 Mar 5.

3.

An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.

Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE, Tilley WD.

Endocr Relat Cancer. 2012 Jul 22;19(4):599-613. doi: 10.1530/ERC-12-0065. Print 2012 Aug.

4.
5.

p62 Regulates the Proliferation of Molecular Apocrine Breast Cancer Cells.

Nozaki F, Hirotani Y, Nakanishi Y, Yamaguchi H, Nishimaki H, Noda H, Tang X, Yamamoto H, Suzuki A, Seki T, Masuda S.

Acta Histochem Cytochem. 2016 Aug 30;49(4):125-30. doi: 10.1267/ahc.16013. Epub 2016 Aug 3.

6.
7.

Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.

Vranic S, Marchiò C, Castellano I, Botta C, Scalzo MS, Bender RP, Payan-Gomez C, di Cantogno LV, Gugliotta P, Tondat F, di Celle PF, Mariani S, Gatalica Z, Sapino A.

Hum Pathol. 2015 Sep;46(9):1350-9. doi: 10.1016/j.humpath.2015.05.017. Epub 2015 Jun 5.

PMID:
26208846
9.

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.

Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R.

Mod Pathol. 2010 Feb;23(2):205-12. doi: 10.1038/modpathol.2009.159. Epub 2009 Nov 6.

10.

Apocrine carcinoma of the breast: a comprehensive review.

Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z.

Histol Histopathol. 2013 Nov;28(11):1393-409. doi: 10.14670/HH-28.1393. Epub 2013 Jun 17. Review.

PMID:
23771415
11.
12.

Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

Gründker C, Föst C, Fister S, Nolte N, Günthert AR, Emons G.

Breast Cancer Res. 2010;12(4):R49. doi: 10.1186/bcr2606. Epub 2010 Jul 14.

13.

IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.

Vranic S, Gurjeva O, Frkovic-Grazio S, Palazzo J, Tawfik O, Gatalica Z.

Appl Immunohistochem Mol Morphol. 2011 Oct;19(5):413-6. doi: 10.1097/PAI.0b013e3182143399.

PMID:
21436679
14.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.

15.
17.

Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.

Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.

J Hematol Oncol. 2012 Jul 11;5:16. doi: 10.1186/1756-8722-5-16.

18.

[Function and prognostic value of tumor suppressor gene LKB1 in human breast carcinoma].

Shen Z, Wu Q, Yue L, Li HC, Shen ZZ, Shao ZM.

Zhonghua Yi Xue Za Zhi. 2005 Jan 5;85(1):15-8. Chinese.

PMID:
15808068
19.

Cutaneous and mammary apocrine carcinomas have different immunoprofiles.

Piris A, Peng Y, Boussahmain C, Essary LR, Gudewicz TM, Hoang MP.

Hum Pathol. 2014 Feb;45(2):320-6. doi: 10.1016/j.humpath.2013.09.007. Epub 2013 Dec 14.

PMID:
24342430
20.

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.

Girgert R, Emons G, Gründker C.

Breast Cancer Res Treat. 2012 Jul;134(1):199-205. doi: 10.1007/s10549-012-1968-x.

Supplemental Content

Support Center